Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer

Rashad Rzazade; Ngoc T Pham; Menekse Turna; Mehmet Dogu Canoglu; Esra Kucukmorkoc; Kezban Berberoglu; Hale Basak Caglar

Stereotactic body radiotherapy in patients with adrenal gland metastases of oligometastatic and oliogoprogressive lung cancer

J Radiosurg SBRT. 2022;8(4):275-282.

Authors

Rashad Rzazade¹, Ngoc T Pham², Menekse Turna¹, Mehmet Dogu Canoglu¹, Esra Kucukmorkoc¹, Kezban Berberoglu³, Hale Basak Caglar¹

Affiliations

¹ Anadolu Medical Center, Department of Radiation Oncology, Gebze, Kocaelı, Turkey.
² Memorial Hermann Texas Medical Center, Department of Radiation Oncology, Houston, Texas, USA.
³ Anadolu Medical Center Department of Nuclear Medicine, Gebze, Kocaelı, Turkey.

PMID: 37416328
PMCID: PMC10322168

Abstract

Objective: To evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) in patients with adrenal gland metastasis (AGM) of oligometastatic lung cancer.

Methods: Between June 2013 and May 2021, 44 patients with oligometastatic lung cancer (51 AGMs) were treated with SBRT. Forty-six (90%) lesions received a biological effective dose (BED₁₀, α/β = 10) of 100 Gy. The primary endpoint was local control (LC). Local control (LC), overall survival (OS), and progression-free survival (PFS) curves were calculated by the Kaplan-Meier method.

Results: The median follow-up was 23 months. The most common histology was non-small cell lung cancer (88.6%). The 1- and 2-year LC rates were both 95% and 91%, respectively. Overall survival was better in patients with solitary AGMs in univariate analysis.

Conclusion: This study demonstrated that SBRT with higher BED is associated with satisfactory LC and low toxicity rates in patients with AGM of oligometastatic lung cancer.

Keywords: Stereotactic body radiotherapy; adrenal gland metastases; biologically effective dose; oligometastatic lung cancer.